Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Weekly Selinexor Regimen Shows Significant Benefit in Pretreated Multiple Myeloma

December 5th 2020

December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.

Axi-Cel Elicits Long-Term Disease Control in Large B-Cell Lymphoma

December 5th 2020

December 5, 2020 - The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.

Racial and Ethnic Related Socioeconomic Disparities Influence Survival Outcomes in AML

December 5th 2020

December 5, 2020 - Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area.

Selinexor Shows Clinical Benefit Across Age Groups in Relapsed/Refractory DLBCL

December 5th 2020

December 5, 2020 - Selinexor demonstrated a clinical benefit in patients with relapsed/refractory diffuse large B-cell lymphoma, regardless of age.

Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis

December 5th 2020

December 5, 2020 - The addition of navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

Oral Azacitidine Prolongs Survival in Patients with AML Following Induction, Consolidation Therapy

December 5th 2020

December 5, 2020 - Azacitidine, was shown to significantly prolong overall survival and relapse-free survival in patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy.

Menin Inhibitor Induces Activity in Patients With Refractory AML

December 5th 2020

December 5, 2020 - KO-539, an oral, selective menin-inhibitor, demonstrated activity in patients with relapsed/refractory acute myeloid leukemia in preliminary findings from the ongoing first-in-human KOMET-001 trial.

Ruxolitinib Demonstrates Superior Efficacy Over Best Available Therapy in Chronic GVHD

December 5th 2020

December 5, 2020 - Ruxolitinib was found to elicit a significantly higher overall response rate, a substantially greater improvement in failure-free survival, and greater symptom improvement versus best available therapy in patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.

Next-Generation CD47 Blocker ALX148/Azacitidine Combo Under Exploration in MDS

December 4th 2020

December 4, 2020 - The first patient with higher-risk myelodysplastic syndrome has been dosed with a novel combination comprised of the next-generation CD47 blocker ALX148 plus azacitidine as part of the phase 1/2 ASPEN-02 study, the first of several planned studies to examine the agent in those with myeloid malignancies.

Novel Approaches Challenge Toxicity Restraints in Classical Hodgkin Lymphoma

December 4th 2020

The ability to increase the efficacy and decrease the toxicity of treatment regimens in classical Hodgkin lymphoma had stood at odds until the introduction of response-adapted treatment approaches, antibody-drug conjugates, and checkpoint inhibitors to the paradigm.

Treatment Considerations in Newly Diagnosed CLL

December 4th 2020

Drs Stilgenbauer and Ghia provide insight on initial treatment considerations for patients with newly diagnosed chronic lymphocytic leukemia.

Dr. Shah on Dosing Tandem Receptor CAR T-Cell Therapy in B-Cell Malignancies

December 3rd 2020

Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

MLL Fusion Proteins Emerge as a Promising Target in AML

December 3rd 2020

Novel agents that disrupt protein-protein interactions in the MLL network may be the key to unlocking new therapeutic avenues for patients with acute leukemias.

Dr. Sehgal on Key Targetable Alterations in AML

December 2nd 2020

Alison R. Sehgal, MD, discusses key targetable alterations in acute myeloid leukemia.

Dr. Ayers on the Evolving Treatment Landscape in CLL

December 2nd 2020

Emily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.

The Therapeutic Toolkit for MDS-Associated Anemia Adds Luspatercept

December 2nd 2020

Joseph G. Jurcic, MD, discusses strategies to optimize patient selection for luspatercept in MDS.

Novel Venetoclax/Decitabine Dosing Schedule Demonstrates Safety, Efficacy in Older Patients With Newly Diagnosed AML

December 1st 2020

The combination of 10-day decitabine with venetoclax elicited responses and was found to be well tolerated in older patients with newly diagnosed acute myeloid leukemia who are ineligible for chemotherapy.

Response-Based Radiation Is Effective, Safe in Pediatric High-Risk Hodgkin Lymphoma

December 1st 2020

The use of response-based consolidation coupled with radiation therapy was found to be effective and well tolerated, with low failure rates, in pediatric patients with high-risk classical Hodgkin lymphoma.

Dr. Nagle on Investigational Cellular Therapies in Multiple Myeloma

November 30th 2020

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Dr. Ruan on Treatment Considerations for Relapsed/Refractory MCL

November 30th 2020

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.